Centerpoint Advisors’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43K | Hold |
545
| – | – | 0.01% | 174 |
|
|
2026
Q1 | $35K | Sell |
545
-5
| -0.9% | -$352 | 0.01% | 175 |
|
|
2025
Q4 | $37K | Hold |
550
| – | – | 0.01% | 179 |
|
|
2025
Q3 | $40K | Hold |
550
| – | – | 0.01% | 182 |
|
|
2025
Q2 | $29K | Hold |
550
| – | – | 0.01% | 193 |
|
|
2025
Q1 | $35K | Hold |
550
| – | – | 0.01% | 185 |
|
|
2024
Q4 | $26K | Hold |
550
| – | – | 0.01% | 227 |
|
|
2024
Q3 | $31K | Hold |
550
| – | – | 0.01% | 219 |
|
|
2024
Q2 | $29K | Hold |
550
| – | – | 0.01% | 217 |
|
|
2024
Q1 | $22K | Hold |
550
| – | – | 0.01% | 232 |
|
|
2023
Q4 | $20K | Sell |
550
-150
| -21% | -$5.65K | 0.01% | 234 |
|
|
2023
Q3 | $27K | Hold |
700
| – | – | 0.01% | 199 |
|
|
2023
Q2 | $25K | Hold |
700
| – | – | 0.01% | 216 |
|
|
2023
Q1 | $27K | Hold |
700
| – | – | 0.01% | 218 |
|
|
2022
Q4 | $40K | Sell |
700
-350
| -33% | -$17.9K | 0.02% | 155 |
|
|
2022
Q3 | $42K | Hold |
1,050
| – | – | 0.02% | 138 |
|
|
2022
Q2 | $46K | Hold |
1,050
| – | – | 0.02% | 143 |
|
|
2022
Q1 | $42K | Sell |
1,050
-50
| -5% | -$1.78K | 0.02% | 158 |
|
|
2021
Q4 | $44K | Hold |
1,100
| – | – | 0.02% | 138 |
|
|
2021
Q3 | $45K | Hold |
1,100
| – | – | 0.02% | 131 |
|
|
2021
Q2 | $50K | Hold |
1,100
| – | – | 0.02% | 128 |
|
|
2021
Q1 | $46K | Hold |
1,100
| – | – | 0.03% | 104 |
|
|
2020
Q4 | $47K | Hold |
1,100
| – | – | 0.03% | 102 |
|
|
2020
Q3 | $29K | Hold |
1,100
| – | – | 0.02% | 105 |
|
|
2020
Q2 | $29K | Hold |
1,100
| – | – | 0.02% | 106 |
|
|
2020
Q1 | $20K | Hold |
1,100
| – | – | 0.02% | 116 |
|
|
2019
Q4 | $20K | Hold |
1,100
| – | – | 0.01% | 139 |
|
|
2019
Q3 | $17K | Hold |
1,100
| – | – | 0.01% | 135 |
|
|
2019
Q2 | $19K | Hold |
1,100
| – | – | 0.02% | 135 |
|
|
2019
Q1 | $18K | Hold |
1,100
| – | – | 0.02% | 134 |
|
|
2018
Q4 | $16K | Hold |
1,100
| – | – | 0.02% | 139 |
|
|
2018
Q3 | $20K | Hold |
1,100
| – | – | 0.02% | 133 |
|
|
2018
Q2 | $19K | Hold |
1,100
| – | – | 0.02% | 145 |
|
|
2018
Q1 | $22K | Hold |
1,100
| – | – | 0.02% | 130 |
|
|
2017
Q4 | $22K | Buy |
+1,100
| New | +$20.2K | 0.02% | 112 |
|
Other funds holding HALO
Centerpoint Advisors's HALO Position: Q2 2026 in Review
Centerpoint Advisors held its Halozyme (HALO) position steady in Q2 2026 at 545 shares worth $43K. The position accounts for 0.01% of the portfolio, ranked #174.
Centerpoint Advisors first reported a position in HALO in Q4 2017 and has held it in 35 quarters since. The position peaked at $50K in Q2 2021. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.
- Centerpoint Advisors held 545 shares of Halozyme worth $43K as of Q2 2026.
- Centerpoint Advisors left its Halozyme share count unchanged in Q2 2026.
- Halozyme made up 0.01% of Centerpoint Advisors's portfolio in Q2 2026, its #174 holding.
- Centerpoint Advisors first reported a position in Halozyme in Q4 2017 and has held it in 35 quarters since.
- Centerpoint Advisors's Halozyme position peaked at $50K in Q2 2021.
- 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.
Based on Centerpoint Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.